Loading...
In January 2016, the FDA approved a single-pill regimen — elbasvir/grazoprevir (EBR/GZR; Zepatier) — to treat adults with chronic hepatitis C virus (HCV) genotypes 1 and 4 infection. In an industry-funded, multinational, open-label phase III trial, researchers randomized 420 HCV-infected patients (genotypes 1, 4, and 6) who had previously been treated with peginterferon/ribavirin (PEG/RBV) to receive daily elbasvir (50 mg)/grazoprevir (100 mg), with or without twice-daily RBV, for 12 or 16 weeks. Of the cohort, 35% had cirrhosis and 64% were previous null or partial responders to PEG/RBV.
Rates of sustained virologic response (SVR) at 12 weeks posttreatment (the primary endpoint) ranged from 92% for 12 weeks of EBR/GZR without RBV to 98% for…